Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook


Chagas Research

  • Target disease: Chagas
  • PartnersTB Alliance, USA; Centre for Drug Candidate Optimisation (CDCO)/ Monash University, Australia; Epichem, Australia; Murdoch University, Australia; Federal University of Ouro Preto (UFOP), Brazil; Institut Pasteur Korea (IPK), South Korea
  • Leadership: Head of Drug Discovery: Eric Chatelain; Project Coordinator: Delphine Launay
  • Project start: April 2012
  • Funding: Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland

  • Objective: Investigate the potential of a nitroimidazole compound that is safer and more efficacious than the current Chagas disease standard of care (benznidazole and/or nifurtimox)

Lead optimization activities have provided a better understanding of the essential features for a drug to be efficacious for the treatment of Chagas disease. This insight will be used to propose a new pre-clinical candidate from the nitroimidazole class that is more potent and with a better safety profile than the drugs currently used (nifurtimox and benznidazole). Work on the nitroimidazooxazines series has concentrated on compounds from the VL-2098 backup programme.

Fexinidazole is a nitroimidazole currently in Phase IIb/III development for HAT. It is very efficacious in a wide variety of rodent Chagas disease models and current work aims to assess fexinidazole suitability for development as a Chagas disease therapy. As safety, pre-clinical and clinical data are available, we aim to rapidly progress fexinidazole to clinical proof-of- concept studies.

Last update: October 2013

Tags: Chagas disease
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License